Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Neurofibromatosis 1 19Neurofibroma, Plexiform 11Neurofibrosarcoma 3Sarcoma 1Peripheral Nervous System Diseases 1Pain 1Optic Nerve Glioma 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neuroblastoma 1Neoplasms, Nerve Tissue 1Meningioma 1Lymphoma, Non-Hodgkin 1Heredodegenerative Disorders, Nervous System 1Glioma 1Ependymoma 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 16Filgrastim 15Etoposide 10Carboplatin 10Peripheral Blood Stem Cell Transplantation 8Melphalan 8Magnetic Resonance Spectroscopy 7Granulocyte Colony-Stimulating Factor 7Busulfan 7Thiotepa 6Temozolomide 6Radiotherapy 6Ifosfamide 6etoposide phosphate 5X-Rays 5Topotecan 5Phantoms, Imaging 5Doxorubicin 5Cisplatin 5Vincristine 4Specimen Handling 4Nuclear Medicine Department, Hospital 4Mesna 4selpercatinib 3sargramostim 3pembrolizumab 3palbociclib 3aldesleukin 3Sirolimus 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × AZD 6244 × CNS × Clear all
NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

University of Alabama at Birmingham

Phase 2 Not yet recruiting
41 enrolled
CNSSarcoma

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡